Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proton Rahman

Showing results (141-150 of 260) with videos related to

Pageof 26
Sort By:
BMC Rheumatology|September 20, 2021
Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week resultsAtul A Deodhar, Philip J Mease, Proton Rahman, et al.
Arthritis Care & Research|August 3, 2016
Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic ArthritisProton Rahman, Lluis Puig, Alice B Gottlieb, et al.
Genes|February 25, 2022
Mutational Landscape of Autism Spectrum Disorder Brain TissueMarc Woodbury-Smith, Sylvia Lamoureux, Ghausia Begum, et al.
The Journal of Rheumatology|April 3, 2019
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab TrialsIain B McInnes, Lluís Puig, Alice B Gottlieb, et al.
Trials|January 10, 2023
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trialChristopher T Ritchlin, Laura C Coates, Philip J Mease, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 22, 2025
Combining Clinical, Genetic and Protein Markers Using Machine Learning Models Discriminates Psoriatic Arthritis Patients From Those With PsoriasisDarshini Ganatra, Max Kotlyar, Amanda Dohey, et al.
Rheumatology (Oxford, England)|October 3, 2017
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Christopher T Ritchlin, et al.
Plos One|May 24, 2014
SMAD3 is associated with the total burden of radiographic osteoarthritis: the Chingford studyErfan Aref-Eshghi, Yuhua Zhang, Deborah Hart, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Arthritis Research & Therapy|March 17, 2018
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)Peter Nash, Philip J Mease, Iain B McInnes, et al.
Pageof 26

Showing results (141-150 of 260) with videos related to

Sort By:
Pageof 26
BMC Rheumatology|September 20, 2021
Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week resultsAtul A Deodhar, Philip J Mease, Proton Rahman, et al.
Arthritis Care & Research|August 3, 2016
Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic ArthritisProton Rahman, Lluis Puig, Alice B Gottlieb, et al.
Genes|February 25, 2022
Mutational Landscape of Autism Spectrum Disorder Brain TissueMarc Woodbury-Smith, Sylvia Lamoureux, Ghausia Begum, et al.
The Journal of Rheumatology|April 3, 2019
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab TrialsIain B McInnes, Lluís Puig, Alice B Gottlieb, et al.
Trials|January 10, 2023
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trialChristopher T Ritchlin, Laura C Coates, Philip J Mease, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 22, 2025
Combining Clinical, Genetic and Protein Markers Using Machine Learning Models Discriminates Psoriatic Arthritis Patients From Those With PsoriasisDarshini Ganatra, Max Kotlyar, Amanda Dohey, et al.
Rheumatology (Oxford, England)|October 3, 2017
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Christopher T Ritchlin, et al.
Plos One|May 24, 2014
SMAD3 is associated with the total burden of radiographic osteoarthritis: the Chingford studyErfan Aref-Eshghi, Yuhua Zhang, Deborah Hart, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Arthritis Research & Therapy|March 17, 2018
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)Peter Nash, Philip J Mease, Iain B McInnes, et al.
Pageof 26